These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 32869703

  • 1. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, Zhou LT, Wei Q, Liu H, Tang RN, Cao JY, Lv LL, Liu BC.
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [Abstract] [Full Text] [Related]

  • 2. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.
    Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X.
    Front Endocrinol (Lausanne); 2023 Nov; 14():1131516. PubMed ID: 37008953
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 4. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

  • 5. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
    Zheng Q, Wang Y, Yang H, Sun L, Zhang P, Zhang X, Guo J, Liu YN, Liu WJ.
    Am J Kidney Dis; 2023 Apr 05; 81(4):434-445.e1. PubMed ID: 36396085
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H, Cheng Q, Wang J, Zhao X, Zhu S.
    J Clin Pharm Ther; 2021 Aug 05; 46(4):999-1009. PubMed ID: 33615523
    [Abstract] [Full Text] [Related]

  • 7. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J, Xie QH, You L, Xu NX, Hao CM.
    Pharmacol Res; 2021 Jan 05; 163():105256. PubMed ID: 33086081
    [Abstract] [Full Text] [Related]

  • 8. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J, Shou X, Xu Y, Jin L, Zhu C, Ye X, Mei Z, Chen P.
    Aging (Albany NY); 2023 Mar 27; 15(6):2237-2274. PubMed ID: 36988549
    [Abstract] [Full Text] [Related]

  • 9. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW, Perkovic V, Badve SV.
    NEJM Evid; 2024 Sep 27; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, Huang Y, Liu YN, Liu WJ.
    Pharmacol Res; 2020 Sep 27; 159():105020. PubMed ID: 32561478
    [Abstract] [Full Text] [Related]

  • 11. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M, Tanaka T, Nangaku M.
    Pharmacol Ther; 2022 Nov 27; 239():108272. PubMed ID: 36031160
    [Abstract] [Full Text] [Related]

  • 12. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
    Zhao H, Li P, Zhang HL, Jia L.
    Ren Fail; 2023 Nov 27; 45(2):2258986. PubMed ID: 37724564
    [Abstract] [Full Text] [Related]

  • 13. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2020 Jul 27; 29(4):414-422. PubMed ID: 32452915
    [Abstract] [Full Text] [Related]

  • 14. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jul 27; 27(7):613-621. PubMed ID: 29975110
    [Abstract] [Full Text] [Related]

  • 15. A spotlight on using HIF-PH inhibitors in renal anemia.
    Odawara M, Nishi H, Nangaku M.
    Expert Opin Pharmacother; 2024 Jul 27; 25(10):1291-1299. PubMed ID: 38994698
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H, Hagiwara H, Kamiya T.
    PLoS One; 2022 Jul 27; 17(9):e0275311. PubMed ID: 36170343
    [Abstract] [Full Text] [Related]

  • 17. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun 27; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S, Guo J, Xie S, Chen J, Yu S, Yu Y.
    Int Urol Nephrol; 2021 Jun 27; 53(6):1139-1147. PubMed ID: 33026571
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
    He J, Jia Z, Zhang A, Bai M.
    Pediatr Nephrol; 2024 Jan 27; 39(1):37-48. PubMed ID: 37284874
    [Abstract] [Full Text] [Related]

  • 20. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
    Wen T, Zhang X, Wang Z, Zhou R.
    Nephron; 2020 Jan 27; 144(11):572-582. PubMed ID: 32866960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.